Abstract: The invention introduces a system for acquiring data on poultry body size, utilizing a baseplate for immobilization. After positioning the poultry, the system adjusts a fixing device on a rod to secure the poultry's knee joints using a fixing clip, thereby stabilizing the poultry's body. A 3D laser scanning lens then conducts comprehensive 3D scanning of the poultry's entire body, transmitting the data to a 3D microcomputer which generates an optimal dynamic model image. This microcomputer organizes and analyzes data from the model using a computer algorithm, ultimately displaying the poultry's body size indices on the 3D microcomputer's display. This method circumvents inaccuracies common with traditional tools like electronic scales, enhancing the speed and precision of poultry body composition data collection.

Abstract: The invention discloses biomarkers associated with residual feed intake of growing chickens in growing period and application thereof, which belongs to the field of poultry breeding technology. These biomarkers include one or multiple components of 13(S)-HOTrE, 20-carboxy-LTB4, Traumatic acid, 15-deoxy-delta-12,14-PGJ2, LysoPC(20:2(11Z,14Z)), phosphorycholine, Sphingosine, malic acid, D-4?-Phosphopantothenate, and Spermidine. The invented biomarkers can realize the identification of the residual feed intake, which has high sensitivity and specificity, and is expected to become a new method for the identification of the residual feed intake.

Abstract: Provided is use of tectorigenin in the preparation of a medicament for treatment of chicken necrotic enteritis. Using tectorigenin for treating chicken necrotic enteritis can significantly reduce the degree of pathological changes in the intestinal tract of chickens with necrotic enteritis, and has a good therapeutic effect on chicken necrotic enteritis caused by Clostridium perfringens.

Abstract: A combined physiological sensor and methods for detecting one or more physiological characteristics of a subject are provided. The combined sensor (e.g., a forehead sensor) may be used to detect and/or calculate at least one of a pulse blood oxygen saturation level, a regional blood oxygen saturation level, a respiration rate, blood pressure, an electrical physiological signal (EPS), a pulse transit time (PTT), body temperature associated with the subject, a depth of consciousness (DOC) measurement, any other suitable physiological parameter, and any suitable combination thereof. The combined sensor may include a variety of individual sensors, such as electrodes, optical detectors, optical emitters, temperature sensors, and/or other suitable sensors. The sensors may be advantageously positioned in accordance with a number of different geometries.

Abstract: A combined physiological sensor and methods for detecting one or more physiological characteristics of a subject are provided. The combined sensor (e.g., a forehead sensor) may be used to detect and/or calculate at least one of a pulse blood oxygen saturation level, a regional blood oxygen saturation level, a respiration rate, blood pressure, an electrical physiological signal (EPS), a pulse transit time (PTT), body temperature associated with the subject, a depth of consciousness (DOC) measurement, any other suitable physiological parameter, and any suitable combination thereof. The combined sensor may include a variety of individual sensors, such as electrodes, optical detectors, optical emitters, temperature sensors, and/or other suitable sensors. The sensors may be advantageously positioned in accordance with a number of different geometries.

Abstract: The present invention provides asymmetrical duplex RNA molecules that are capable of effecting sequence-specific gene silencing. The RNA molecule comprises a first strand and a second strand. The first strand is longer than the second strand. The RNA molecule comprises a double-stranded region formed by the first strand and the second strand, and two ends independently selected from the group consisting of 5?-overhang, 3?-overhang, and blunt end. The RNA molecules of the present invention can be used as research tools and/or therapeutics.

Abstract: The present invention relates to the composition of a nanoparticle based on a magnesium salt, and methods of drug delivery using the nanoparticle. A preferred embodiment uses magnesium phosphate, with or without a shell to deliver aiRNA and/or siRNA. The nanoparticles of the present invention are also effective when administered orally.

Abstract: The present invention provides asymmetrical duplex RNA molecules that are capable of effecting sequence-specific gene silencing. The RNA molecule comprises a first strand and a second strand. The first strand is longer than the second strand. The RNA molecule comprises a double-stranded region formed by the first strand and the second strand, and two ends independently selected from the group consisting of 5?-overhang, 3?-overhang, and blunt end. The RNA molecules of the present invention can be used as research tools and/or therapeutics.

Abstract: The present invention relates to the composition of a nanoparticle based on a magnesium salt, and methods of drug delivery using the nanoparticle. A preferred embodiment uses magnesium phosphate, with or without a shell to deliver aiRNA and/or siRNA. The nanoparticles of the present invention are also effective when administered orally.

Abstract: Provided is use of tectorigenin in the preparation of a medicament for treatment of chicken necrotic enteritis. Using tectorigenin for treating chicken necrotic enteritis can significantly reduce the degree of pathological changes in the intestinal tract of chickens with necrotic enteritis, and has a good therapeutic effect on chicken necrotic enteritis caused by Clostridium perfringens.

Abstract: The present invention relates to the composition and method of use of Stat3 pathway inhibitors or cancer stem cell inhibitors in combination treatment of cancer.

Abstract: The present invention provides asymmetrical duplex RNA molecules that are capable of effecting sequence-specific gene silencing. The RNA molecule comprises a first strand and a second strand. The first strand is longer than the second strand. The RNA molecule comprises a double-stranded region formed by the first strand and the second strand, and two ends independently selected from the group consisting of 5?-overhang, 3?-overhang, and blunt end. The RNA molecules of the present invention can be used as research tools and/or therapeutics.

Abstract: The present invention relates to the use of a novel class of cancer stem cell pathway (CSCP) inhibitors; to methods of using such compounds to treat refractory, recurrent, or metastatic cancers; to methods of selective killing cancer cells by using such corn pounds with specific administration regimen; to methods of targeting cancer stem cells by inhibiting Stat3 pathway; to methods of using novel compounds in the treatment of conditions or disorders in a mammal related to aberrant Stat3 pathway activity; and to processes for preparing such compounds and intermediates thereof and to the pharmaceutical compositions of relevant compounds, and to the specific methods of administration of these compounds.

Abstract: The invention provides naphthofuran compounds, polymorphs of naphthofuran compounds, naphthofuran compounds in particle form, purified compositions that contain one or more naphthofuran compounds, purified compositions that contain one or more naphthofuran compounds in particle form, and methods of using these naphthofuran compounds, polymorphs, purified compositions and/or particle forms to treat subjects in need thereof.

Abstract: Methods for treating advanced thymoma and thymic carcinoma in a subject comprising administering and kits comprising at least one paclitaxel compound and at least one compound of formula (I) (2-acetylnaphtho[2,3-b]furan-4,9-dione) as disclosed herein.

Abstract: The present invention provides asymmetrical duplex RNA molecules that are capable of effecting sequence-specific gene silencing. The RNA molecule comprises a first strand and a second strand. The first strand is longer than the second strand. The RNA molecule comprises a double-stranded region formed by the first strand and the second strand, and two ends independently selected from the group consisting of 5?-overhang, 3?-overhang, and blunt end. The RNA molecules of the present invention can be used as research tools and/or therapeutics.

Abstract: The present invention provides asymmetrical duplex RNA molecules that are capable of effecting sequence-specific gene silencing. The RNA molecule comprises a first strand and a second strand. The first strand is longer than the second strand. The RNA molecule comprises a double-stranded region formed by the first strand and the second strand, and two ends independently selected from the group consisting of 5?-overhang, 3?-overhang, and blunt end. The RNA molecules of the present invention can be used as research tools and/or therapeutics.

Abstract: A combined physiological sensor and methods for detecting one or more physiological characteristics of a subject are provided. The combined sensor (e.g., a forehead sensor) may be used to detect and/or calculate at least one of a pulse blood oxygen saturation level, a regional blood oxygen saturation level, a respiration rate, blood pressure, an electrical physiological signal (EPS), a pulse transit time (PTT), body temperature associated with the subject, a depth of consciousness (DOC) measurement, any other suitable physiological parameter, and any suitable combination thereof. The combined sensor may include a variety of individual sensors, such as electrodes, optical detectors, optical emitters, temperature sensors, and/or other suitable sensors. The sensors may be advantageously positioned in accordance with a number of different geometries.

Abstract: The present invention relates to the use of a novel class of cancer stem cell pathway (CSCP) inhibitors; to methods of using such compounds to treat refractory, recurrent, or metastatic cancers; to methods of selective killing cancer cells by using such compounds with specific administration regimen; to methods of targeting cancer stem cells by inhibiting Stat3 pathway; to methods of using novel compounds in the treatment of conditions or disorders in a mammal related to aberrant Stat3 pathway activity; and to processes for preparing such compounds and intermediates thereof, and to the pharmaceutical compositions of relevant compounds, and to the specific methods of administration of these compounds.

Abstract: The invention provides naphthofuran compounds, polymorphs of naphthofuran compounds, naphthofuran compounds in particle form, purified compositions that contain one or more naphthofuran compounds, purified compositions that contain one or more naphthofuran compounds in particle form, and methods of using these naphthofuran compounds, polymorphs, purified compositions and/or particle forms to treat subjects in need thereof.